Covered recipient · General Payments record
ANNA F FARAGO
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2019–2020
$101,967.51
- Reported across 86 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2020 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $27,730.00 | 8 |
| Travel and Lodging | $6,025.46 | 4 |
| Food and Beverage | $243.96 | 6 |
By paying entity
PY2020 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $19,145.40 | 14 |
| Bayer HealthCare Pharmaceuticals Inc. | $11,549.02 | 2 |
| AstraZeneca UK Limited | $2,055.00 | 1 |
| PFIZER INC. | $1,250.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2020 (18)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020
- Source files
- Dataset page · Bulk file · PY2019 , PY2020
- Generated from
- OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.